The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

ABSTRACT: This is a randomized, prospective, multicenter, Proof of Concept, Phase II clinical trial Study. The main objective of the study is to evaluate the efficacy (meant as overall response rate ORR) of TT (targeted Therapy) vs SoC (standard of Care) in patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed at least 1 line of treatment and no more than 2 as defined by the current version of the AIOM (Italian Association of Medical Oncology) guidelines. Patients are included if surgery is contraindicated.

DISEASE(S): Patients With Progressive Disease (recurrent And/or Metastatic) Of Breast Cancer, Metastatic Gastro-intestinal Tumors, Non Small Cell Lung Cancer (nsclc) Or Others. Patients Should Have Completed At Least 1 Line Of Treatment And No More Than 2 As Defined By The Current Version Of The Aiom Guidelines. Patients Are Included If Surgery Is Contraindicated.,Gastrointestinal Neoplasms,Other Cancer,Gastrointestinal Cancer,Non Small Cell Lung Cancer,Pazienti Affetti Da Malattia Progressiva (recidivante E/o Metastatica) Del Carcinoma Mammario, Del Tumore Metastatico Gastro-intestinale, Del Carcinoma Polmonare Non A Piccole Cellule (nsclc) O Altri. I Pazienti Devono Aver Completato Almeno 1 Linea Di Trattamento E Non Più Di 2, Come Definito Dall’attuale Versione Delle Lineeguida Aiom. I Pazienti Possono Essere Inclusi Se L'intervento Chirurgico È Controindicato.,Comedocarcinoma Of Breast,Lung Squamous Cell Carcinoma Metastatic,Breast Cancer,Carcinoma Gastrointestinal

PROVIDER: 2354830 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR